Creo Medical (CREO) AI Stock Analysis

• Market Cap: £46.40M
• Dividend Yield: N/A
• Average Volume (3M): 975.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 412,473,330
• 10 Day Avg. Volume: 668,834
• 30 Day Avg. Volume: 975,484
• PEG Ratio: -0.17
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 17.63
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 10.50p ▼(-6.67% Downside)

Creo Medical's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics are poor due to negative earnings. These factors collectively contribute to a low overall score.

Creo Medical Business Overview & Revenue Model

Company Description

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.

How the Company Makes Money

Creo Medical generates revenue through the sale of its proprietary medical devices and consumables used in surgical procedures. The company’s primary revenue streams come from the direct sale of its CROMA system and related accessories to hospitals and surgical centers. Additionally, Creo may engage in partnerships with healthcare institutions and distributors to expand its market reach and facilitate product adoption. The company might also generate income through training programs for healthcare professionals and potential licensing agreements for its technologies, further enhancing its earnings potential.

Creo Medical Financial Statement Overview

Summary

Creo Medical is facing significant financial challenges with declining revenues and persistent net losses. While there is a slight improvement in debt management, the overall financial health remains weak due to continued cash flow deficits and reduced equity.

Income Statement

Creo Medical has experienced a significant drop in total revenue from $30.8M in 2023 to $4M in 2024, resulting in a negative revenue growth rate. The gross profit margin decreased from 49.7% in 2023 to 47.5% in 2024. Net profit margin worsened due to substantial losses, with a net income of -$28.7M in 2024. The EBIT and EBITDA margins remain deeply negative, reflecting ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio improved slightly as total debt decreased. However, stockholders' equity also declined, indicating potential concerns in financial structuring. The equity ratio is relatively healthy, with equity covering a significant portion of total assets, but overall asset levels have decreased year-over-year.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash burn from operations. Free cash flow is also negative, though it improved slightly from 2023 to 2024. The free cash flow to net income ratio is unfavorable, suggesting insufficient cash generation to cover operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.20M	4.00M	30.80M	27.17M	25.16M	9.43M
Gross Profit	1.00M	1.90M	15.30M	10.01M	9.02M	2.44M
EBITDA	-9.50M	-26.10M	-20.70M	-27.62M	-27.54M	-21.77M
Net Income	16.90M	-28.70M	-21.70M	-26.94M	-24.59M	-20.32M
Balance Sheet
Total Assets	68.80M	65.00M	76.60M	75.34M	100.61M	92.46M
Cash, Cash Equivalents and Short-Term Investments	20.50M	8.70M	18.50M	13.10M	43.53M	45.09M
Total Debt	4.20M	4.40M	8.30M	11.70M	10.56M	12.36M
Total Liabilities	7.90M	22.60M	16.80M	25.93M	27.29M	29.66M
Stockholders Equity	60.90M	42.40M	59.80M	49.40M	73.32M	62.81M
Cash Flow
Free Cash Flow	15.30M	-22.60M	-22.80M	-28.26M	-32.10M	-16.66M
Operating Cash Flow	15.30M	-22.20M	-21.60M	-24.99M	-25.98M	-16.09M
Investing Cash Flow	-3.30M	15.30M	-18.30M	-6.03M	-7.87M	-21.16M
Financing Cash Flow	-600.00K	16.20M	29.80M	400.00K	31.99M	1.33M

Creo Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Positive. The current price of 11.25 is above the 20-day moving average (MA) of 11.10, below the 50-day MA of 11.76, and below the 200-day MA of 13.06, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 47.68 is Neutral, neither overbought nor oversold. The STOCH value of 54.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:CREO.

Creo Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RUA	54 Neutral	£7.91M	1,275.00	0.08%	―	87.72%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	51 Neutral	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
IHC	44 Neutral	£18.16M	-1.59	-51.63%	―	31.78%	10.27%
CREO	42 Neutral	£46.40M	-1.88	―	―	―	―
OBI	41 Neutral	£63.50M	―	―	―	63.25%	8.94%

Creo Medical Corporate Events

Creo Medical Announces Capital Markets Day for Investors

Creo Medical Group plc has announced a Capital Markets Day event for investors and analysts to be held on 19 November 2025 in London. This event underscores the company’s commitment to engaging with stakeholders and highlights its focus on the growing field of minimally invasive surgical endoscopy, potentially impacting its market position and stakeholder relations.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Creo Medical Reschedules Capital Markets Day Due to Clinical Priorities

Creo Medical Group plc has announced the rescheduling of its Capital Markets Day due to a scheduling conflict involving a keynote speaker who is engaged in a significant clinical procedure. This decision underscores the importance of the clinician’s role in Creo’s clinical program and highlights the company’s commitment to patient care. The rescheduling may impact stakeholder engagement and the company’s market communication strategy, with further details to be announced later.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Creo Medical Advances in Cancer Treatment and Operational Efficiency

Creo Medical announced significant advancements in its operations and financial performance. The company has initiated clinical studies for its MicroBlate Flex device and reported improved operating efficiency with a 24% reduction in costs. The strategic sale of a 51% stake in CME to Micro-Tech has strengthened their commercial platform and balance sheet. Despite a decrease in total sales, the company has achieved a 40% increase in revenue from continuing operations, reflecting wider clinical adoption of its products. The outlook remains positive with expectations of strong revenue growth and self-sustaining cashflows.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Creo Medical to Announce Interim Results and Host Investor Presentation

Creo Medical Group plc announced it will release its unaudited interim results for the first half of 2025 on September 22, 2025. The company will host a live online presentation for investors on September 24, 2025, to discuss these results, reflecting its commitment to transparency and engagement with shareholders. This announcement underscores Creo’s ongoing efforts to strengthen its market position in the medical device industry, particularly in the field of minimally invasive surgical endoscopy.

The most recent analyst rating on (GB:CREO) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Creo Medical stock, see the GB:CREO Stock Forecast page.

Creo Medical’s Speedboat® Technology Demonstrates Life-Changing Impact

Creo Medical Group has highlighted the successful use of its Speedboat® technology through a testimonial from Liz Thomas, who avoided major surgery thanks to the procedure. This case underscores the clinical value of Speedboat® in treating early-stage colorectal cancer and its potential to reduce surgical burdens. The ongoing pilot with the Aneurin Bevan University Health Board in Wales is showing promising results, which could lead to broader adoption across the NHS, supporting Creo’s growth strategy.